Ingrid Teigland Akay is a medical doctor and experienced investment professional with background in healthcare, consumer goods and technology.
During her investment career, Ingrid has invested into and supported start-up companies globally in different phases of development, from R&D to commercial stage.
As a medical doctor, she gained broad clinical experience working in diverse fields such as general medicine, surgery and psychiatry, with exposure to both the public and private sector in several European countries including Scandinavia, Germany and the UK.
Ingrid holds a medical degree from Medizinische Hochschule Hannover, Germany, and an MBA with Finance Concentration from London Business School.
Walter is a seasoned healthcare investor with previous experience in strategy consulting and basic research.
As a scientist Walter worked at Harvard University and the University of Vienna focusing on molecular mechanisms of cholesterol transport in cells and whole organisms. His research was published in high impact journals like Cell and EMBO.
After joining the Boston Consulting Group as a member of the Healthcare Practice Team Walter advised pharmaceutical companies and PE firms in the context of commercial projects as well as during buy and sell side M&A transactions.
In 2009 walter joined the London office of one of the largest specialist healthcare VC firms. Being responsible for deal sourcing, due diligence and exit management Walter gained significant experience by successfully investing into and exiting portfolio companies.
Siro has over 15 years of international experience across the whole research, development, commercialization, and investment process in new technologies.
Siro brings a wealth of experience as a serial entrepreneur having co-founded and held CEO roles in several start-ups within the life sciences field.
He gained investment experience at leading hedge and VC funds, and previously worked as Project Leader at BCG. He started his career in drug development at Novartis.
Siro holds a Masters in Finance from LBS, a PhD summa cum laude in Molecular Biology and a MSc in Chemistry with honours from the Autonoma University of Madrid, studied Computer Science Engineering at UNED, and speaks English, German, and Spanish fluently.
Mirela Brox has experience from over a decade in the finance industry. She started her career at DNB before working as an adviser at the Oslo Stock Exchange.
She subsequently moved to the Norwegian Financial Authorities as a Senior Advisor and furthermore worked in the section for market conduct with main tasks including investigation of suspicious transactions (insider trading and market manipulation).
Mirela holds a double degree in Finance from BI and in Cell Biology from NTNU and is a Certified Financial Analyst from NHH. Mirela speaks English, Norwegian and Bosnian fluently.
Dr. Barbut is an experienced clinician scientist and entrepreneur. She trained as an internist and neurologist in the UK and the USA.
Subsequently she became an associate Attending Physician and Professor of Neurology at Weill-Cornell Medical Center heading the Neurovascular Division and the Stroke Research Program.
Dr. Barbut is author of close to 200 issued or pending patents, mostly relating to neuroprotection, hypothermia, the treatment of cerebral ischemia, pain and neuromodulation. She is also lead or senior author on >50 articles.
She left academia in 2000 after founding the second of her 7 biotech companies and has since achieved successful exits incl trade sales and IPO. She is currently Founder and Board Chair at Sarentis Therapeutics. She is also a board member at Astuce, Novo Biosciences, Israel Brain Technologies and an advisor to Serpin Pharmaceuticals, Greenhill Ventures and ADDF (Alzheimer foundation).
Dr. Seizinger is an accomplished scientist and specialist for drug development. He trained as a Medical Doctor and received a PhD from the Max Planck Institute of Psychiatry & Neurology in Munich, Germany. Dr. Seizinger has authored more than 100 publications, including a number of papers in Nature, Science and Cell, and has been the recipient of numerous scientific awards.
At Bristol-Meyers Squibb Dr. Seqizinger was responsible for Oncology Drug Discovery and VP of Corporate and Academic Alliances.
Since leaving the BMS, Dr. Seizinger has held multiple CEO, board, chairman and executive chairman roles in pharmaceutical companies including Aprea AB, Opsona Therapeutics and several others.
Florian Eckhardt is the CEO of DST Diagnostische Systeme & Technologien GmbH in Schwerin, Germany and a visiting professor of IE Business School, Madrid. At IE, he lectures strategy and strategic management in the MBA and Master in Biotechnology program.
He previously worked as an investment manager at Inventages VC and has more than 15 years of experience in the diagnostic industry. Throughout his career in diagnostics, he worked in various roles including product development and business development for Epigenomics AG, Brahms AG, and ThermoFisher Inc.
Dr Eckhardt holds a Ph.D. & Master in Biology from the Universität Freiburg and an International Executive MBA from IE Business School Business.
Duncan was educated in Edinburgh and went to the University of Leeds where he studied Biochemistry and Microbiology. He has an M.Phil and Ph.D. from the University of Cambridge where he was also a post doctoral research fellow.
After leaving academia Duncan joined Morgan Stanley where he was a top-ranked healthcare analyst and from 1997 to 2008 acting as Managing Director leading the firm’s global healthcare equity research team. He was the lead analyst on the European pharmaceutical industry stocks and led the equity research part of the initial public offerings of numerous companies including Wellcome PLC, Sulzer Medica, Biora, deCODE Genetics, Almirall, Grifols and, Grupo Rovi.
Duncan is currently a Partner at East West Capital Partners, a global Healthcare Investment firm.